Search peptides, terms, sources/
Growth hormone axis

GHRP-2

Also known as: Pralmorelin · growth hormone-releasing peptide-2

Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK; Japan licenses it only as a diagnostic test. No trial shows a health benefit.

UK status and evidence last reviewed .

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Limited evidence (level 2 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

4 findings at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. GHRP-2 is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Human trials4 human trials · 1 human observational

What is GHRP-2?

GHRP-2 (pralmorelin) is a synthetic six-amino-acid peptide that stimulates the pituitary gland to release growth hormone. It is not licensed in the UK, Japan licenses it only as a diagnostic agent for growth hormone deficiency, and the human research is hormone-response and diagnostic testing, not trials of any health benefit.

Class
Growth hormone-releasing peptide (GHRP) hexapeptide
Origin
Fully synthetic
UK status
Not licensed in the UK
Best study type
Human trials
Evidence last reviewed

How does GHRP-2 work?

GHRP-2 is understood to act through the growth hormone secretagogue receptor, which the body's own hormone ghrelin also activates, and so to push the pituitary to release growth hormone. In human studies it also raised prolactin, ACTH and cortisol. A large growth hormone rise is a measurement, not evidence that GHRP-2 improves body composition, recovery or any other health outcome.

The mechanism in more detail

GHRP-2 belongs to the growth hormone-releasing peptides, a class of synthetic growth hormone secretagogues. These are understood to act through the growth hormone secretagogue receptor, the same receptor the body’s own hormone ghrelin activates, and to push the pituitary to release growth hormone. In human studies, GHRP-2 produced a large rise in growth hormone, and the response was larger in younger than in older men and weaker in men with more abdominal fat.

It is not a selective stimulant. In a head-to-head study with hexarelin, GHRP-2 also raised prolactin, ACTH and cortisol. The strong growth hormone response in healthy people is the basis for using GHRP-2 as a test substance, and Japan authorises it for that purpose only.

A large growth hormone response in healthy volunteers is a physiological measurement. It is not evidence that GHRP-2 improves body composition, recovery or any other health outcome, and no trial that tests such an outcome was identified.

Classification and structure

Names
GHRP-2; Pralmorelin; growth hormone-releasing peptide-2
Class
Growth hormone-releasing peptide (GHRP) hexapeptide
Origin
Fully synthetic
Structure
Synthetic hexapeptide (six amino acids).
Routes used in the research
Intravenous injection or infusion in the cited human studies where the route is stated. This reflects study methodology, not a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

GHRP-2 has 6 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

6 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
14001

Licensed in Japan as a diagnostic agent Not graded

Japan's medicines regulator (PMDA) lists a pralmorelin hydrochloride product, GHRP Kaken 100 Injection from Kaken Pharmaceutical, with one authorised indication: the diagnosis of growth hormone secretion deficiency. The package insert shows marketing began in February 2005. It is authorised as a test substance, not as a treatment.

Study type
Regulatory-clinical source
Population
Not applicable (regulatory record)
Source
1 Pharmaceuticals and Medical Devices Agency (PMDA) et al., 2025

Limitation: A Japanese-language regulator record.

Limitations in full

A Japanese-language regulator record. It shows the authorised use and marketing history, not clinical performance. The approval number is 21600AMZ00573; the page read did not state the approval date. Not a UK or EU licence.

Adult GH deficiency test, Japan Limited

In 71 adults with pituitary tumours tested before surgery, the GHRP-2 test and an arginine test were compared with the insulin tolerance test, the long-standing reference test for adult growth hormone deficiency. GHRP-2 produced much higher growth hormone peaks than the reference test. Against a severe-deficiency cut-off set by the reference test, the GHRP-2 test identified 81.3% of deficient patients (sensitivity) and correctly cleared 94.5% of the others (specificity). The authors concluded it is an acceptable alternative test in Japanese patients.

Study type
Human trial
Population
Human adults aged 18 to 65 with pituitary tumours, before surgery
Source
2 Kinoshita et al., 2013

Limitation: One Japanese cohort, all with pituitary tumours.

Limitations in full

One Japanese cohort, all with pituitary tumours. The abstract does not report side effects. Accuracy depends on the cut-off chosen for the reference test, and the authors say cut-offs should be set for each population.

GH response varies with age and fat Limited

In 22 men (11 younger, 11 older) whose sex hormones were held steady with drugs, GHRP-2 given with arginine released about 1.3 times more growth hormone in the younger men. More abdominal visceral fat was linked to a weaker response, and higher IGF-I to a stronger one. This describes how the body's response varies between men. It does not show that GHRP-2 changes body composition or health.

Study type
Human trial
Population
Human men, 11 younger (mean age about 24) and 11 older (mean age about 64)
Source
3 Veldhuis et al., 2009

Limitation: Men only, small groups, a hormone-response measurement and not a health outcome.

Head-to-head with hexarelin Limited

In seven young volunteers given each compound in separate sessions, GHRP-2 and hexarelin produced similar, large rises in growth hormone. Both also raised prolactin, ACTH and cortisol. The study measured hormone levels only.

Study type
Human trial
Population
Human young adult volunteers (sex not stated in the abstract), 7 participants
Source
4 Arvat et al., 1999

Limitation: Seven volunteers in short sessions.

Limitations in full

Seven volunteers in short sessions. The main aim of the study was a third compound; GHRP-2 and hexarelin were comparators.

Arginine plus GHRP-2 during exercise Limited

In 9 men and 9 women who exercised, growth hormone release ranked the same in both sexes: arginine and GHRP-2 together produced the most, then GHRP-2 alone, then arginine alone, then saline. Exercise raised the individual effects of arginine and GHRP-2 but reduced the extra, greater-than-additive effect that the pair has at rest.

Study type
Human trial
Population
Human volunteers, 9 men and 9 women (women in the early follicular phase)
Source
5 Wideman et al., 2000

Limitation: Small physiology study.

Limitations in full

Small physiology study. It measures hormone release, not any benefit from exercise or from the peptide.

Adrenal insufficiency test, 2026 Preliminary

In a retrospective review of 69 patients in Japan who had both a CRH stimulation test and an insulin tolerance test, a low peak cortisol (under 12 micrograms per decilitre) on the GHRP-2 test was specific to hypothalamic secondary adrenal insufficiency. The authors conclude the insulin tolerance test is still needed when hypothalamic dysfunction is suspected, and that the GHRP-2 cortisol response may help support the diagnosis when that test cannot be used.

Study type
Human observational
Population
Human patients in Japan, retrospective review, 69 patients
Source
6 Okada et al., 2026

Limitation: Retrospective, single-country review, published ahead of print and not independently replicated.

Limitations in full

Retrospective, single-country review, published ahead of print and not independently replicated. Only the abstract record was read.

What safety findings have been reported?

1 safety finding is recorded for GHRP-2. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Raises ACTH, cortisol and prolactin

In a head-to-head study in seven volunteers, GHRP-2 raised prolactin, ACTH and cortisol alongside growth hormone, with responses similar to those of hexarelin. In that study GHRP-2 was therefore not a selective growth hormone stimulant. The study measured hormone levels only and was not designed to look for harm.

Source
4 Arvat et al., 1999

What is GHRP-2's UK regulatory status?

Marketing authorisation
No UK marketing authorisation found. A check of the MHRA Products database active substance index on 14 November 2026 found no entry for GHRP-2 or pralmorelin.
Prescription status
Not applicable in the UK, no licensed UK product was found to classify.
Medicine class
Not a licensed medicine in the UK. Licensed in Japan as a single-purpose diagnostic agent (GHRP Kaken 100 Injection, Kaken Pharmaceutical), with marketing from February 2005 according to the PMDA package insert.
MHRA position
No GHRP-2-specific MHRA notice was identified in this review. The review did not include a systematic search of MHRA enforcement releases. Supplying an unlicensed product for human use as a medicine falls under the Human Medicines Regulations 2012.
Authorised use
None in the UK. In Japan: diagnosis of growth hormone secretion deficiency only (PMDA package insert).
Other restrictions
None identified beyond the general Human Medicines Regulations 2012 framework. In sport, the WADA 2026 Prohibited List (in force from 1 January 2026) names GHRP-2 (pralmorelin) under S2.2.4, growth hormone secretagogues and growth hormone-releasing peptides.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. GHRP-2 is recorded as not licensed in the UK (checked 14 November 2026).

References

7 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. Pharmaceuticals and Medical Devices Agency (PMDA), Japan. Marketing authorisation holder: Kaken Pharmaceutical Co., Ltd. (2025). PMDA medicinal product information: GHRP Kaken 100 Injection (pralmorelin hydrochloride), package insert. PMDA medicinal product information (Japan) · Original ↗
  2. Kinoshita Y, Tominaga A, Usui S, Arita K, Sakoguchi T, Sugiyama K, Kurisu K (2013). The arginine and GHRP-2 tests as alternatives to the insulin tolerance test for the diagnosis of adult GH deficiency in Japanese patients: a comparison. Endocrine JournalHuman clinical trial · DOI 10.1507/endocrj.ej12-0230 · PMID 23079545 · Original ↗
  3. Veldhuis JD, Bowers CY (2009). Factors other than sex steroids modulate GHRH and GHRP-2 efficacies in men: evaluation using a GnRH agonist/testosterone clamp. Journal of Clinical Endocrinology and MetabolismHuman clinical trial · DOI 10.1210/jc.2008-2767 · PMID 19351731 · Original ↗
  4. Arvat E, Di Vito L, Lanfranco F, Broglio F, Giordano R, Benso A, Muccioli GP, Deghenghi R, Ghigo E (1999). Tyr-Ala-hexarelin, a synthetic octapeptide, possesses the same endocrine activities of hexarelin and GHRP-2 in humans. Journal of Endocrinological InvestigationHuman clinical trial, RCT · DOI 10.1007/bf03350886 · PMID 10195374 · Original ↗
  5. Wideman L, Weltman JY, Patrie JT, Bowers CY, Shah N, Story S, Veldhuis JD, Weltman A (2000). Synergy of L-arginine and GHRP-2 stimulation of growth hormone in men and women: modulation by exercise. American Journal of Physiology: Regulatory, Integrative and Comparative PhysiologyHuman clinical trial · DOI 10.1152/ajpregu.2000.279.4.r1467 · PMID 11004017 · Original ↗
  6. Okada N, Nakagawa T, Murahashi N, Kurosu T, Kusuda S, Kaneko C, Hishida Y, Nakamura Y, Asai S, Yokota K, Sone M (2026). Differentiating hypothalamic from pituitary adrenal insufficiency: underlying causes and diagnostic utility of the corticotropin-releasing hormone and growth hormone-releasing peptide-2 stimulation tests. Endocrine JournalHuman observational · DOI 10.1507/endocrj.ej26-0192 · PMID 42732957 · Original ↗
  7. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about GHRP-2

What is GHRP-2?

GHRP-2 (pralmorelin) is a synthetic six-amino-acid peptide that stimulates the pituitary gland to release growth hormone. It is not licensed in the UK, Japan licenses it only as a diagnostic agent for growth hormone deficiency, and the human research is hormone-response and diagnostic testing, not trials of any health benefit. Read what it is.

Is GHRP-2 licensed in the UK?

PeptGuru records GHRP-2's UK status as: Not licensed in the UK. No UK marketing authorisation found. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on GHRP-2 show?

PeptGuru records 6 research findings for GHRP-2: 4 from human trials, 1 from a human observational study and 1 from a regulatory or other record. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for GHRP-2?

1 safety finding is recorded, including: raises ACTH, cortisol and prolactin. Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for GHRP-2?

All 7 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • New profile · GHRP-2 added: 6 findings and 1 safety items, each checked against its published record, with UK status checked on the MHRA register.

How findings are graded: the grading method. All changes.

  • GHRP-6Growth hormone-releasing…

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. Human studies are short hormone-response and diagnostic work; no trial shows a health benefit.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • HexarelinExamorelin

    Synthetic hexapeptide that triggers growth hormone release. Not licensed in the UK. In a long-term human study the response faded and IGF-I and body composition did not change.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • IpamorelinIPA

    Synthetic growth hormone secretagogue studied for growth hormone release. Not licensed in the UK; human evidence is one small pharmacokinetic study.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • SermorelinSermorelin acetate

    Synthetic growth-hormone-releasing hormone fragment studied in children with growth hormone deficiency. Not licensed in the UK; evidence is mainly from before 2000.

    Growth hormone axisHuman trialsEvidence reviewed
    LimitedNot licensed in the UK

Compare GHRP-2 with GHRP-6

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.